Drug Insight: different mechanisms of action of tumor necrosis factor antagonists—passive-aggressive behavior?

被引：0
|
作者：
William FC Rigby
机构：
[1] WFC Rigby is a Professor of Medicine,
[2] Microbiology and Immunology at Dartmouth Medical School,undefined
[3] Lebanon,undefined
[4] NH,undefined
[5] USA.,undefined
来源：
Nature Clinical Practice Rheumatology | 2007年 / 3卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Etanercept, adalimumab and infliximab all specifically antagonize tumor necrosis factor (TNF), but with differential clinical efficacy. Differences in their pharmacology and mechanisms of action, and disease heterogeneity, might account for this therapeutic disparity, as might reverse signaling by transmembrane TNF in response to anti-TNF antibodies, all of which are reviewed here.
引用
收藏
页码：227 / 233
页数：6
相关论文
共 50 条
  • [41] Drug Insight:: anti-tumor necrosis factor therapy for inflammatory arthropathies during reproduction, pregnancy and lactation
    Skomsvoll, Johan F.
    Wallenius, Marianne
    Koksvik, Hege S.
    Rodevand, Erik
    Salvesen, Kjell A.
    Spigset, Olav
    Kvien, Tore K.
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2007, 3 (03): : 156 - 164
  • [42] Similarities in the mechanisms of action of pulse corticosteroids and anti-tumor necrosis factor α therapy in rheumatoid arthritis
    Roberts-Thomson, PJ
    Smith, MD
    Ahern, MJ
    ARTHRITIS AND RHEUMATISM, 1998, 41 (03): : 564 - 565
  • [43] Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms
    Kim, Min-Soo
    Lee, Seung-Hyun
    Song, Moo-Young
    Yoo, Tae Hyoung
    Lee, Byung-Kyu
    Kim, Yong-Sung
    JOURNAL OF MOLECULAR BIOLOGY, 2007, 374 (05) : 1374 - 1388
  • [44] Proinflammatory Action of the Antiinflammatory Drug Infliximab in Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
    Nedjai, Belinda
    Hitman, Graham A.
    Quillinan, Niamh
    Coughlan, Robert J.
    Church, Leigh
    McDermott, Michael F.
    Turner, Mark D.
    ARTHRITIS AND RHEUMATISM, 2009, 60 (02): : 619 - 625
  • [45] Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease
    Battat, Robert
    Lukin, Dana
    Scherl, Ellen J.
    Pola, Suresh
    Kumar, Anand
    Okada, Lauren
    Yang, Lei
    Jain, Anjali
    Siegel, Corey A.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (09) : 1443 - 1451
  • [46] SIMILAR MECHANISMS OF ACTION OF DEFINED POLYSACCHARIDES AND LIPOPOLYSACCHARIDES - CHARACTERIZATION OF BINDING AND TUMOR-NECROSIS-FACTOR-ALPHA INDUCTION
    OTTERLEI, M
    SUNDAN, A
    SKJAKBRAEK, G
    RYAN, L
    SMIDSROD, O
    ESPEVIK, T
    INFECTION AND IMMUNITY, 1993, 61 (05) : 1917 - 1925
  • [47] Similarities in the mechanisms of action of pulse corticosteroids and anti-tumor necrosis factor α therapy in rheumatoid arthritis -: Reply
    Maini, RN
    Feldmann, M
    ARTHRITIS AND RHEUMATISM, 1998, 41 (03): : 565 - 565
  • [48] Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action
    Collamer, Angelique N.
    Guerrero, Karen T.
    Henning, Jeffery S.
    Battafarano, Daniel F.
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (07): : 996 - 1001
  • [49] Tumor necrosis factor-α stimulates lactate dehydrogenase A expression in porcine cultured Sertoli cells:: Mechanisms of action
    Boussouar, F
    Grataroli, R
    Ji, JW
    Benahmed, M
    ENDOCRINOLOGY, 1999, 140 (07) : 3054 - 3062
  • [50] Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice
    Vande Casteele, Niels
    Feagan, Brian G.
    Wolf, Douglas C.
    Pop, Anca
    Yassine, Mohamed
    Horst, Sara N.
    Ritter, Timothy E.
    Sandborn, William J.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (08) : 1346 - 1355
12345